Versartis Inc., of Redwood City, Calif., said it completed patient enrollment in a Phase I trial of VRS-317, a once-monthly form of recombinant human growth hormone. The primary objective of the study is to evaluate the safety and tolerability of a single subcutaneous dose of the drug.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter